564 related articles for article (PubMed ID: 25174341)
21. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
22. Glioblastoma cancer stem cell biology: Potential theranostic targets.
Sharifzad F; Ghavami S; Verdi J; Mardpour S; Mollapour Sisakht M; Azizi Z; Taghikhani A; Łos MJ; Fakharian E; Ebrahimi M; Hamidieh AA
Drug Resist Updat; 2019 Jan; 42():35-45. PubMed ID: 30877905
[TBL] [Abstract][Full Text] [Related]
23. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
24. Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands.
Im CN
IUBMB Life; 2016 Mar; 68(3):173-7. PubMed ID: 26818439
[TBL] [Abstract][Full Text] [Related]
25. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.
Jin F; Zhao L; Guo YJ; Zhao WJ; Zhang H; Wang HT; Shao T; Zhang SL; Wei YJ; Feng J; Jiang XB; Zhao HY
Brain Res; 2010 Jun; 1336():103-11. PubMed ID: 20388502
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
27. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.
Spencer DA; Auffinger BM; Murphy JP; Muroski ME; Qiao J; Gorind Y; Lesniak MS
Curr Cancer Drug Targets; 2017; 17(3):236-254. PubMed ID: 27993114
[TBL] [Abstract][Full Text] [Related]
28. Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.
Safari M; Khoshnevisan A
J Stem Cells; 2015; 10(4):271-85. PubMed ID: 27144829
[TBL] [Abstract][Full Text] [Related]
29. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
30. A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.
Giuliani P; Zuccarini M; Carluccio M; Ziberi S; Di Iorio P; Caciagli F; Ciccarelli R
Curr Drug Targets; 2018; 19(16):1871-1881. PubMed ID: 29484991
[TBL] [Abstract][Full Text] [Related]
31. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
[TBL] [Abstract][Full Text] [Related]
32. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
33. Adenosine Depletion as A New Strategy to Decrease Glioblastoma Stem-Like Cells Aggressiveness.
Niechi I; Uribe-Ojeda A; Erices JI; Torres Á; Uribe D; Rocha JD; Silva P; Richter HG; San Martín R; Quezada C
Cells; 2019 Oct; 8(11):. PubMed ID: 31671624
[TBL] [Abstract][Full Text] [Related]
34. Frontiers in targeting glioma stem cells.
Frosina G
Eur J Cancer; 2011 Mar; 47(4):496-507. PubMed ID: 21185169
[TBL] [Abstract][Full Text] [Related]
35. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
[TBL] [Abstract][Full Text] [Related]
36. The role of octamer binding transcription factors in glioblastoma multiforme.
Rooj AK; Bronisz A; Godlewski J
Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
38. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
39. Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling.
Kim B; Jung N; Lee S; Sohng JK; Jung HJ
Phytother Res; 2016 Nov; 30(11):1833-1840. PubMed ID: 27468969
[TBL] [Abstract][Full Text] [Related]
40. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]